IMS Health brought market access firm HGS Europe into the fold last month.

The UK company, which was founded in 1998 by Angela and Graeme McFarland, has expertise in understanding the market access piece of a launch as well as what cost-effectiveness ­gatekeepers such as NICE are looking for.

Mike Sanvoisin, the GM of UK and Ireland for IMS, told MM&M that IMS will be looking to link its own real-world data assets with HGS’s strategies in order to help European payers see how drugs are performing in the real world. “Payers want to see that investments they make are having an effect,” Sanvoisi said. “That’s where we see the synergy of HGS coming in.”

From the January 01, 2014 Issue of MM+M - Medical Marketing and Media